AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers as part of AstraZeneca’s Ambition Zero Carbon program.
AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than currently used respiratory medicine propellants, AstraZeneca announced on Feb. 22, 2022.
Patients with asthma and chronic obstructive pulmonary disease (COPD) often need inhaled medicines, many of which are pressurized metered dose inhalers (pMDIs). In many of these medicines a propellant, which contains small amounts of a type of greenhouse gas (GHG), is used to deliver the medicine into the lungs. According to the press release, respiratory diseases affect hundreds of millions of people around the world, creating a significant clinical need for pMDIs, which are important device options for patients.
AstraZeneca’s integration of their near-zero GWP propellant HFO-1234ze is intended to reduce respiratory healthcare carbon emissions without restricting patient choice or risking improvement in health outcomes.
This development of next-generation respiratory inhalers is part of AstraZeneca’s flagship sustainability program, Ambition Zero Carbon. The company also announced that the entirety of its imported electricity now comes from renewable sources, and that the company has achieved a 59% reduction in it5s Scope 1 and 2 greenhouse gas (GHG) emissions since 2015.
"We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030,” said Pascal Soriot, CEO of AstraZeneca, in the press release. “Our collaboration with Honeywell demonstrates AstraZeneca’s commitment to advancing sustainable healthcare innovation, with the aim of improving outcomes for patients while reducing our environmental footprint.”
Source: AstraZeneca
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.